Table 2.
Overall and time-dependent risk of SI
| Results | nbDMARD | All TNF | ETN | INF | ADA |
|---|---|---|---|---|---|
| Follow–up, pyrs | 9259 | 36 230 | 15 874 | 9622 | 10 733 |
| Number of SIs | 296 | 1512 | 609 | 441 | 462 |
| Rate/1000 pyrs (95% CI) | 32 (28, 36) | 42 (40, 44) | 38 (35, 42) | 46 (42, 50) | 43 (39, 47) |
| Unadjusted HR | Ref. | 1.5 (1.3, 1.7) | 1.4 (1.2, 1.6) | 1.6 (1.4, 1.9) | 1.4 (1.2, 1.7) |
| adjHRa (95% CI) | Ref. | 1.2 (1.1, 1.5) | 1.2 (1.0, 1.4) | 1.3 (1.1, 1.6) | 1.3 (1.1, 1.5) |
| Follow-up, months | |||||
| 0–6 | Ref. | 1.8 (1.2, 2.6) | 1.8 (1.2, 2.7) | 1.7 (1.1, 2.6) | 1.8 (1.2, 2.7) |
| 6–12 | Ref. | 1.4 (0.9, 2.0) | 1.3 (0.8, 2.0) | 1.4 (0.9, 2.2) | 1.4 (0.9, 2.1) |
| 12–24 | Ref. | 1.2 (0.8, 1.6) | 1.1 (0.8, 1.5) | 1.1 (0.7, 1.5) | 1.3 (0.9, 1.8) |
| 24–36 | Ref. | 0.9 (0.6, 1.3) | 0.8 (0.6, 1.2) | 1.2 (0.8, 1.8) | 0.8 (0.6, 1.3) |
aAdjusted for age, gender, COPD, diabetes, smoking, disease duration, DAS, HAQ, entry year, steroid use and MTX use. pyrs: patient-years.